IO102-IO103疫苗联合帕博利珠单抗一线治疗晚期黑色素瘤的III期试验
这项开放标签III期试验将407例未经治疗的晚期黑色素瘤患者按1:1随机分配,接受IO102-IO103(85 μg)联合帕博利珠单抗或帕博利珠单抗单药治疗。联合组中位PFS为19.4个月,单药组为11.0个月(HR 0.77,95%CI 0.58-1.00,P=0.0558),未达到预设统计学显著性阈值(P≤0.045)。联合组未增加≥3级治疗相关不良事件或严重不良事件频率。
要点
- 联合组中位PFS 19.4个月 vs 单药组11.0个月,HR 0.77,P=0.0558,未达统计学显著性。
- PD-L1阴性亚组中位PFS 16.6 vs 3.0个月(HR 0.54,95%CI 0.35-0.85)。
- 联合组≥3级治疗相关不良事件14.5% vs 15.6%,未增加显著全身毒性。
核心结论
- IO102-IO103联合帕博利珠单抗一线治疗晚期黑色素瘤较帕博利珠单抗单药延长PFS,但主要终点未达到统计学显著性。
- 联合治疗耐受性良好,未增加显著全身毒性。
研究设计与样本
- 开放标签、III期随机对照试验,纳入407例未经治疗的晚期黑色素瘤患者。
- 按1:1随机分配至皮下IO102-IO103(85 μg each)联合静脉帕博利珠单抗200 mg每3周,或帕博利珠单抗单药,最长2年。
- 主要终点为盲法独立中心评审按RECIST v1.1评估的PFS。
主要发现
- 联合组中位PFS 19.4个月(95%CI 9.7至未达到),单药组11.0个月(95%CI 6.0-14.8),HR 0.77(95%CI 0.58-1.00),P=0.0558,未达到统计学显著性阈值(P≤0.045)。
- PD-L1阴性肿瘤患者中位PFS联合组16.6个月 vs 单药组3.0个月(HR 0.54,95%CI 0.35-0.85)。
- 抗PD-1初治患者中位PFS联合组24.8个月 vs 单药组11.0个月(HR 0.74,95%CI 0.56-0.98)。
- BRAF突变肿瘤或乳酸脱氢酶升高患者中亦观察到联合组PFS延长。
- 联合组≥3级治疗相关不良事件发生率14.5% vs 15.6%,严重不良事件32.0% vs 32.3%。
关键数值与推荐
- 主要终点统计学显著性阈值设定为P≤0.045。
- IO102-IO103剂量为85 μg each,皮下注射;帕博利珠单抗200 mg静脉每3周,最长2年。
临床怎么用
- 该联合方案在未经治疗的晚期黑色素瘤中显示出PFS延长趋势,尤其在PD-L1阴性、抗PD-1初治、BRAF突变或LDH升高患者中。
- 联合治疗未增加显著全身毒性,但主要终点未达统计学显著性,需进一步评估获益风险。
局限性
- 主要终点未达到预设统计学显著性阈值(P=0.0558 vs P≤0.045)。
- 开放标签设计可能影响部分终点评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: IO102-IO103, an investigational, immune-modulatory cancer vaccine, targets both tumor cells and immune-suppressive cells within the tumor microenvironment through activation and expansion of T cells against indoleamine 2,3-dioxygenase 1-positive and/or programmed death ligand 1 (PD-L1)-positive cells. PATIENTS AND METHODS: This open-label, phase III trial randomly assigned 407 patients with untreated advanced melanoma in a 1:1 ratio to receive subcutaneous IO102-IO103 (85 μg each) plus pembrolizumab 200 mg intravenously every 3 weeks or pembrolizumab alone for up to 2 years. The primary endpoint was progression-free survival (PFS) by blinded independent central review per RECIST v1.1. RESULTS: The median PFS was 19.4 months [95% confidence interval (CI) 9.7 to not reached] for IO102-IO103 plus pembrolizumab versus 11.0 months (95% CI 6.0-14.8) for pembrolizumab [hazard ratio (HR) (95% CI) 0.77 (0.58-1.00), P = 0.0558]; the statistical significance threshold (P ≤ 0.045) was missed. A longer PFS was observed in the combination arm across most subgroups, notably in patients with PD-L1-negative tumors [median PFS 16.6 versus 3.0 months (HR 0.54, 95% CI 0.35-0.85)], anti-PD-1 naïve patients [24.8 versus 11.0 months (HR 0.74, 95% CI 0.56-0.98)], proto-oncogene B-Raf (BRAF)-mutated tumors, or elevated lactate dehydrogenase. There was no increase in the frequency of treatment-related adverse events grade ≥3 (14.5% versus 15.6%) or of serious adverse events (32.0% versus 32.3%) in the vaccine arm. Local vaccine-related injection site reactions were reported in 56.0% of patients and were mostly grade 1/2. CONCLUSIONS: IO102-IO103 plus pembrolizumab prolonged PFS compared with pembrolizumab alone in patients with advanced melanoma in the first-line setting; however, statistical significance was missed for the primary endpoint. The combination was well tolerated with no added significant systemic toxicity. These data show the potential benefit of this combination in untreated advanced melanoma.
引用
- Hassel JC, Arance A, Carlino MS, et al. IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma. Ann Oncol. 2026. PMID: 42025759. doi:10.1016/j.annonc.2026.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。